DENTSPLY SIRONA director granted 10K shares

MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.

DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a grant of 10,000 shares of Common Stock on June 12, 2026 at a reported value of $10.14 per share. This compensation-related award increased his directly held stake to 61,668.534 shares, rather than reflecting an open-market purchase.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider MAZELSKY JONATHAN JAY

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,000	$10.14	$101K

Holdings After Transaction: Common Stock — 61,668.534 shares (Direct)

Key Figures

Shares granted: 10,000 shares Grant value per share: $10.14 per share Shares held after grant: 61,668.534 shares

3 metrics

Shares granted 10,000 shares Common Stock grant on June 12, 2026

Grant value per share $10.14 per share Reported price for the 10,000-share award

Shares held after grant 61,668.534 shares Director’s direct Common Stock holdings following transaction

Key Terms

Grant, award, or other acquisition, Common Stock, non-derivative

3 terms

Grant, award, or other acquisition financial

"The transaction is coded as "Grant, award, or other acquisition" on the Form 4."

Common Stock financial

"The reported transaction involves 10,000 shares of Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"The filing classifies the transaction as non-derivative, involving direct equity rather than options."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DENTSPLY SIRONA (XRAY) disclose for Jonathan Jay Mazelsky?

DENTSPLY SIRONA reported that director Jonathan Jay Mazelsky received a grant of 10,000 shares of Common Stock. The transaction is coded as a grant or award, indicating compensation, not an open-market purchase of shares.

Was the DENTSPLY SIRONA (XRAY) insider transaction a purchase or a grant?

The transaction was a grant or award acquisition, not a market purchase. It is coded "A" on Form 4, meaning shares were awarded as compensation rather than bought on the open market by the director.

At what price was the DENTSPLY SIRONA (XRAY) share grant valued?

The 10,000-share grant to director Jonathan Jay Mazelsky was valued at $10.14 per share. This figure represents the price per share reported in the Form 4 for the compensation-related stock award.

How many DENTSPLY SIRONA (XRAY) shares does Jonathan Jay Mazelsky hold after the grant?

After the 10,000-share award, Jonathan Jay Mazelsky directly holds 61,668.534 shares of DENTSPLY SIRONA Common Stock. This total reflects his position immediately following the reported Form 4 transaction.

Does the DENTSPLY SIRONA (XRAY) Form 4 indicate any stock sales by the director?

No stock sales are reported in this Form 4. The filing shows only a single acquisition coded as a grant or award, increasing Jonathan Jay Mazelsky’s direct holdings without any corresponding disposition of DENTSPLY SIRONA shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAZELSKY JONATHAN JAY

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NORTH CAROLINA 28277

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		A		10,000	A	$10.14	61,668.534	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jessica Nielsen Causey, Attorney-in-Fact for Jonathan Jay Mazelsky	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)